Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

CONCLUSION: Higher rates of serious infection, HZ, lymphopenia, and NMSC were observed with upadacitinib versus adalimumab in PsA; slightly elevated rates for most of these TEAEs were seen with upadacitinib in PsA versus axSpA. Upadacitinib 15 mg demonstrated a generally consistent safety profile across disease states with no new safety signals identified.TRIAL REGISTRATION: SELECT-AXIS 1: NCT03178487; SELECT-AXIS 2: NCT04169373; SELECT-PsA 1: NCT03104400; SELECT-PsA 2: NCT03104374.PMID:38683479 | DOI:10.1007/s40744-024-00671-4

Source: Herpes - April 29, 2024 Category: Infectious Diseases Authors: Gerd R Burmester Jayne Stigler Andrea Rubbert-Roth Yoshiya Tanaka Valderilio F Azevedo Derek Coombs Ivan Lagunes Ralph Lippe Peter Wung Lianne S Gensler Source Type: research